APPG on Pneumococcal Disease Prevention - Events

All-Party Parliamentary Group on Pneumococcal Disease Prevention in the Developing World

All-Party Parliamentary Group on Pneumococcal Disease Prevention in the Developing World

Mission Statement

Meetings and Events

Resources
The following documents help provide background on the work undertaken by the APPG on Pneumococcal Disease Prevention in the Developing World, the GAVI Alliance and PneumoADIP.
Advanced Market Commitment Launch Five Nations and the Bill & Melinda Gates Foundation have Launched the Advance Market Commitment for Vaccines to Combat Pneumococcal Disease in Poor Nations US$1.5 billion pilot programme expected to save 5.4 million lives, protecting children from pneumonia and meningitis
Pneumococcal Facts Quick facts on pneumococcal disease and prevention by vaccination
What is PneumoADIP? The PneumoADIP Mission PneumoADIP's mission is to improve child survival and health by accelerating the evaluation of and access to, new life-saving pneumococcal vaccines for the world's poorest children. PneumoADIP aims to achieve its mission by reducing and sharing risks with the private sector and in return obtaining a more sustainable, affordable supply of vaccine for developing countries. An effective and successful PneumoADIP could lead to millions of lives saved through earlier and faster access to vaccines.
GAVI Advanced Market Commitment Briefing Paper Efforts to increase access to immunization have saved millions of lives in both industrialized and developing countries. However, in the world's poorest countries gaps in coverage and vaccine availability remain. Sadly, every year, 3 million people die from diseases that could have been prevented by vaccines, 99% of whom live in the developing world.
Pneumonia and Pneumococcal Disease: Key Facts This document lists the key facts surrounding pneumonia, pneumococcal and vaccines
HM Treasury information on the Advanced Market Commitment The Advance Market Commitment (AMC) is an innovative, market-based mechanism with the potential to save millions of lives by accelerating access to vaccines in the world's poorest countries, vaccines that would not otherwise be available for many years. The first AMC will target pneumococcal disease, bringing potentially life-saving vaccines more quickly to 100 million children and preventing over 5 million deaths by 2030.
Early Day Motion No 284: Pneumococcal Disease Pevention in the Developing World Early Day Motion No 284: Pneumococcal Disease in the Developing World, was tabled on the 15th of November, 2007 by Chair of the All-Party Parliamentary Group for Pneumococcal Disease Prevention in the Developing World, Dr Desmond Turner MP. For the full list of signatories go to:http://edmi.parliament.uk/EDMi/EDMDetails.aspx?EDMID=34395&SESSION=891
APPG letter to the British Medical Journal On the 22nd of January, the British Medical Journal (BMJ) published a letter to the editor from the Chair of the All-Party Parliamentary Group for Pneumococcal Disease Prevention in the Developing World, Dr Des Turner MP and fellow Group member, Dr Richard Taylor MP in response to an article concerning the treatment of severe pneumonia in children under five from the developing world.